Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials
Authors' conclusion
Superior weight reduction with tirzepatide versus comparators appears to be independent of reported N/V/D or GI AEs.
Study context
- Population
- Participants with T2D in SURPASS-1 to −5, as monotherapy or add-on to background antihyperglycaemic medication(s); subgroups by self-reported N/V/D or gastrointestinal (GI) adverse events (AEs)
- Participants
- 6,263 participants5 RCTs
- Comparison
- Once-weekly tirzepatide vs comparators
- Primary endpoint
- Change from baseline in body weight within each trial and subgroup (N/V/D or GI AEs yes/no)
- Follow-up
- Primary timepoint
Methodological detailssubgroup analysis, mediation analysis
- Subgroup analysis
- Mediation analysis
Primary result
As reported in the abstract
Mean weight change with tirzepatide by N/V/D subgroup
Mean weight reduction with tirzepatide, participants reporting N/V/D
−6.2 to −14.9 kg
Mean weight reduction with tirzepatide, participants not reporting N/V/D
−6.2 to −13.3 kg
Further findings
Mediation analysis: contribution of N/V/D and GI AEs to weight difference tirzepatide vs comparators
- Minimal contribution of N/V/D and GI AEs
- <6%
Safety
Most common GI AEs with tirzepatide
- Nausea
- 12%-24%
- Diarrhoea
- 12%-22%
- Vomiting
- 2%-13%
- Transient and of mild-to-moderate severity
Original publication
Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials. Diabetes Obes Metab. Published 18 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →